[Therapy of extrapyramidal motor disturbances by tiaprid (author's transl)].
In animal experiments Costall and Naylor (1977) showed that Tiaprid, a benzamide derivative of the orthopamids, inhibits dopamine receptors in the caudate nucleus and putamen but not in the mesolimbic system. Involuntary movements in patients with extrapyramidal movement disorders were reduced by 300 mg daily. Good results were obtained in 56% of 93 patients (25 in this study and 68 from the literature). On the whole the efficacy of Tiaprid seems far better than that of neuroleptics, and side effects are definitely fewer.
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects; D001480:Basal Ganglia Diseases / Q000150:complications / Q000188:drug therapy*; D001549:Benzamides / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology; D011954:Receptors, Dopamine / Q000187:drug effects; D013976:Tiapamil Hydrochloride / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D001549:Benzamides; D011954:Receptors, Dopamine; D013976:Tiapamil Hydrochloride
Behandlung extrapyramidaler Bewegungsstörungen mit Tiaprid.